13Dec
13Dec
TetraGenetics Partners with LifeArc to Humanize New Drugs and Perform IND-Enabling Studies
TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases and pain, today announced a partnership with LifeArc®, the UK-based medical research charity. The collaboration brings together the drug discovery skills of TetraGenetics with the antibody humanization and development capabilities of LifeArc. Under the agreement LifeArc will humanize up to five new drug leads discovered by TetraGenetics and may support pre-IND (Investigational New Drug) studies for selected programs. TetraGenetics will manage the regulatory applications and the subsequent clinical trials for...
11Dec
Springfield teen thanks community for help in regaining vision
A Springfield boy hosted a thank you concert for the community who helped him raise funds for his eSight glasses. Read more >>
11Dec
Mass Innovation Nights 105
Wasabi will be featured at #MIN105. Read more >>
09Dec
When the Investment Banker Comes Calling
Boston Harbor Angel members, Ziad Moukheiber and David Powsner, are the hosts of Failure – the Podcast, a podcast about about business failures, focusing on startups and emerging companies. In episode four, Moukheiber and Powsner chat with Jack Langworthy, of Covington Associates, as he looks at startups from an investment banker’s perspective. Tune in >>
07Dec
How This Prenatal Vitamin Startup has Achieved Fast-Paced Growth
Dan Aziz stood outside of pharmacies surveying pregnant women for market research before starting his company, Luna Pharmaceuticals, which developed Premama. Read more >>
07Dec
TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies Against KCa3.1
TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced a collaboration with ModiQuest Research, a Dutch biotechnology company with a suite of technologies for the discovery and optimization of monoclonal antibodies including those directed against difficult target antigens with low immunogenicity. Read more >>
07Dec
Myomo, Inc. Announces Full Exercise of Underwriter’s Over-Allotment Option in Follow-On Public Offering
Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that Roth Capital Partners, the underwriter of Myomo’s follow-on offering, exercised in full its option to purchase 626,250 shares of common stock and accompanying warrants to purchase 626,250 shares of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately $1.5 million. Read more >>
05Dec
Two Babson Alumni Businesses to Appear on ‘Meet the Drapers’—a New TV Show Turning Viewers into Investors
Green Piñata will appear in Episode Four on Sunday, December 10 at 6 p.m. ET. Read more >>
03Dec